In a 70-year-old man with a three-year history of pancytopenia and multiple blood transfusions, what are the possible causes and differential diagnoses?

Differential Diagnosis and Causes of Chronic Pancytopenia in a 70-Year-Old Man

In a 70-year-old man with 3-year pancytopenia requiring multiple transfusions, myelodysplastic syndrome (MDS) is the most likely diagnosis and should be prioritized in your workup, as MDS has a median age of diagnosis of 70 years and is the leading cause of chronic pancytopenia in this age group 1.

Primary Differential Diagnoses (Ranked by Likelihood)

1. Myelodysplastic Syndromes (MDS) - MOST LIKELY

• Incidence peaks at age 70 years (40-50 cases/100,000) 1
• Characterized by ineffective hematopoiesis causing chronic cytopenias with transfusion dependence
• History of multiple transfusions over 3 years strongly suggests this diagnosis
• Secondary MDS from prior chemotherapy/radiation exposure has particularly poor prognosis 1
• Key diagnostic features: Hypercellular marrow with dysplasia, with or without blast excess 1

2. Acute Myeloid Leukemia (AML)

• Accounts for 26% of new pancytopenia cases in adults 2
• Can evolve from MDS (one-fourth to one-third of MDS cases progress to AML) 1
• More severe cytopenias than non-clonal causes 2
• Look for circulating blasts, nucleated RBCs, or immature granulocytes on peripheral smear 2

3. Aplastic Anemia

• Represents 5-18% of pancytopenia cases 2, 3
• Presents with hypocellular marrow (unlike MDS which is typically hypercellular)
• More common in younger patients but can occur at any age

4. Other Hematologic Malignancies

• Non-Hodgkin lymphoma (6% of cases) 2
• Hairy cell leukemia (5% of cases) 2
• Multiple myeloma (rare but documented in elderly) 4

Secondary Causes to Exclude

Nutritional/Metabolic

• Vitamin B12/folate deficiency (17% of cases in some series) 3
• Megaloblastic anemia can cause severe pancytopenia but typically responds quickly to replacement

Chronic Liver Disease

• Accounts for 15% of pancytopenia cases 3
• Look for stigmata of cirrhosis, splenomegaly, portal hypertension
• Mechanism: hypersplenism and decreased thrombopoietin production

Autoimmune/Rheumatologic

• Systemic lupus erythematosus, rheumatoid arthritis (5% of cases) 3
• Usually have other systemic manifestations

Infectious

• HIV-related changes (2% of cases) 2
• Disseminated histoplasmosis (associated with hemophagocytic lymphohistiocytosis) 5
• Chronic infections causing bone marrow suppression

Drug-Induced

• Methimazole, chemotherapy agents, immunosuppressants 6
• Critical caveat: Drug-induced pancytopenia can occur with minimal exposure and may be irreversible 6

Diagnostic Algorithm

Step 1: Peripheral Blood Smear Review

• Look for: Circulating blasts, dysplastic features, nucleated RBCs, immature granulocytes
• Significance: Presence strongly suggests clonal disorder (64% of pancytopenia has clonal etiology) 2

Step 2: Severity Assessment

• More severe cytopenias favor clonal disorders over non-clonal causes 2
• Document transfusion requirements (>20-60 RBC units suggests significant disease) 1

Step 3: Exclude Reversible Causes

• Vitamin B12, folate levels
• Liver function tests, viral hepatitis panel
• HIV testing
• Autoimmune workup (ANA, anti-dsDNA) if clinically indicated
• Medication review for marrow-suppressive drugs

Step 4: Bone Marrow Examination - ESSENTIAL

• Bone marrow aspiration and trephine biopsy are mandatory for definitive diagnosis 1, 7
• Assess cellularity (hypercellular vs. hypocellular)
• Evaluate for dysplasia, blast percentage, fibrosis
• Cytogenetic analysis (karyotype) - critical for MDS diagnosis and prognosis 1
• Next-generation sequencing/molecular profiling for gene mutations (TP53, del 5q, complex karyotype) 1, 7

Step 5: Risk Stratification

• If MDS confirmed, use IPSS or IPSS-R scoring 1
• Assess for del(5q), chromosome 5/7 abnormalities, complex cytogenetics 1
• Determine higher-risk vs. lower-risk disease to guide treatment

Critical Clinical Pitfalls

1. Do not delay bone marrow biopsy - Most causes require marrow examination for diagnosis 7, 8

2. Iron overload assessment - With 3 years of transfusions, this patient likely has significant iron overload

   • Check serum ferritin (>1000-2500 μg/L indicates overload) 1
   • Consider cardiac MRI (T2*) if ferritin significantly elevated 1
   • Iron chelation strongly recommended if transplant candidate 1

3. Age-appropriate evaluation - At 70 years, inherited bone marrow failure syndromes are unlikely unless family history present 9

4. Clonal vs. non-clonal distinction - Nearly two-thirds of new pancytopenia in elderly North American adults is clonal 2, making MDS/AML the statistical favorites

5. Therapy-related considerations - Ask specifically about prior chemotherapy, radiation, or benzene exposure 1

Management Implications Based on Diagnosis

If Higher-Risk MDS (which chronic transfusion dependence suggests):

• Azacitidine is first-line treatment 1
• Evaluate for allogeneic stem cell transplant if age <70 and no major comorbidities 1
• Iron chelation mandatory if transplant candidate 1

If Lower-Risk MDS:

• Erythropoiesis-stimulating agents (ESAs) if no del(5q) 1
• Lenalidomide if del(5q) present 1
• Luspatercept after ESA failure in MDS-RS 1

The 3-year duration with ongoing transfusion requirements strongly suggests this is not a reversible cause and mandates urgent hematology referral with bone marrow evaluation 7, 8.